Our data further demonstrated that Oct-4 expression in LC-CD133+ is involved in tumor malignancy of lung cancers and exhibits refractory properties for chemoradiotherapy in cancer stem-like cells. This evidence concerns the gene PROM1 and lung carcinoma.